Sonmar 5-Aminolaevulimic acid (ALA)-induced porphyrin photosensitisation is an attractive option for photodynamic therapy (PDT) 
Photodynamic therapy (PDT) is a promising non-thermal laser technique which produces localised tissue necrosis with light following administration of a photosensitising drug. The drug is activated by light of a specific wavelength matched to its absorption spectrum. In the presence of oxygen. the activated photosensitiser causes the production of the cytotoxic species, singlet oxygen (Weishaupt et al., 1976) . Animal studies have shown that. in contrast to thermal techniques (as with the Nd: YAG laser) or radiotherapy, which usually affects all parts of the wall of a viscus. damaging collagen fibrils and smooth muscle, PDT is more selective, sparing the collagen fibrils and hence enabling healing predominantly by regeneration (Barr et al.. 1987a) . However, the present status of PDT is far from ideal. Besides the problems of precise light delivery and monitoring there are still difficulties in finding the ideal sensitiser. Clinically, the most used sensitisers are the derivatives of haematoporphynrn (HPD). Efforts have been directed at identifying the active component and it has been variously described as dihaematoporphyrin ether (Dougherty et al., 1984) or ester (Kessel, 1985) . But there are several disadvantages regarding this sensitiser, in particular cutaneous photosensitivity may last for up to 3 months. Furthermore, an ideal sensitiser should have high tumour selectivity, which is not achieved by HPD (or indeed by any of the currently available photosensitisers) and therefore damage to normal tissue also occurs, although this may be acceptable if it is accompanied by safe healing. which is usually the case (Bown, 1990) .
5-Aminolaevulimnc acid (ALA) itself is not a sensitiser but a naturally occurring precursor in the haem biosynthetic pathway. In this pathway the synthesis of ALA is controlled by a regulatory feedback inhibition (Rimington. 1966; Marriott. 1968 ). By administering excess exogenous ALA to both in vitro systems and whole animals. it has been shown that the natural regulatory mechanism can be bypassed and the final stage in the synthesis, the conversion of protoporphyrin IX (PPIX) to haem involving the enzyme ferrochelatase, can become overloaded. As a result, porphyrin intermediates of the biosynthetic pathway, particularly PPIX. accumulate (Malik and Djaldetti, 1979; Sima et al.. 1981) . PPIX is a potent photosensitiser. Successful photosensitisation has been demonstrated not only in in vitro experiments (Malik and Lugaci, 1987) and animal tumour models (Bedwell et al.. 1992) but also in clinical trials. Topical or systemic application of ALA in the treatment of basal cell carcinomas (Kennedy and Pottier 1992) or tumours of the mouth (Grant et al., 1993) respectively showed promising results. We have also shown that PDT with ALA can produce necrosis in gastrointestinal tumours (Regula et al., 1995) . However, these preliminary results showed that the effect of PDT using ALA at the maximum oral dose that could be tolerated is very superficial (typically only 1 mm depth of necrosis) compared with results using HPD. The purpose of this paper is to look at ways in which the treatment conditions using ALA might be varied to get deeper necrosis. particularly as our own recent laboratory experiments have demonstrated that we can elicit up to 8 mm of necrosis in transplanted tumours in the hamster pancreas (Regula et al.. 1994) . Two approaches were used, optimising the total drug and light doses and fractionating the light dose.
Initially, the relative importance of the drug and light dose was studied. In previous studies using aluminium sulphonated phthalocyamnne (AlSPc) we have shown that there is a threshold tissue concentration of photosensitiser required to produce photodynamic damage in the normal colon with a specified light dose (Barr et al.. 1987b (Henderson et al.. 1983: Gibson and Hilf. 1985) and in vivo studies (Cowled and Forbes. 1985) . Fingar and Henderson (1987) wxere not all the same (5J then 20J. 12.5J then 12.5J. 20J then -,J and 25 J in one fraction).
To assess the effect of light fractionation at ALA doses closer to those used clinically. a small number of experiments was also done at ALA doses of 50 and 100 mg kg-i.v. All animals wxere killed 7'2 h after laser treatment and the area of the PDT lesions measured at post mortem. Fixe animals wxere used for each set of xalues tested.
Results
Threshold studies Lesions xxere seen in the treated colons three days after PDT as well defined. oxal shaped. necrotic ulcers. The maximum and minimum diameter of necrosis was measured macroscopically in all specimens. In the limited number of specimens examined microscopically, there was always close correlation between the dimensions of the lesion as measured macroscopically and microscopically. and so for the remainder of the study, only macroscopic measurements were made. The area of necrosis was plotted as a function of the applied energy for each ALA dose and is shown in Figure 1 . With the lowest drug dose of 25 mg kg-', there was no difference in lesion size compared with unsensitised control animals irradiated with the same light doses (50, 100 or 150J). For higher drug doses, initially the photodynamic effect increased with increasing light dose. but then reached a plateau ( Figure  1 ). The same data is plotted in Figure 2 to show the area of necrosis as a function of the administered dose of ALA. For the higher energies of 100 and 150 J, a significant increase of the lesion size over that seen in controls could be achieved if the ALA dose was 50 mg kg-' or more. For the lower energies, this required elevating the dose to 100 mg kg-' (75 and 50 J) or 200 mg kg-' (25 J).
Photodegradation of ALA-induced PPIX was studied using ex vivo fluorescence imaging. ). An excitation spectrum of untreated colon was recorded from 600 to 650 nm using detection at 700 nm which showed that peak PPIX fluorescence excitation efficiency occurs at 635 nm; at 630 nm the efficiency was only 10% lower. thus little should be gained by using 635 instead of 630 nm for PDT treatment.
Fractionated irradiation studies
In the second part of these studies we examined the influence of fractionating the light dose. Table I shows the results using just two fractions of light, but varying the interval between fractions from 10 to 900 s. Table II shows the results of dividing the light dose into five equal fractions. but once again varying the interval between fractions from 10 to 900 s. Table III shows the results of varying the number of fractions from 1 to 25. with equal fractions and a fixed interval of 50 s between fractions. Table IV shows the results using just two fractions with an interval of 300 s with the same total light dose of 25 J, but varying the size of the first fraction from 5 to 20J. Finally. (J) investigation was to study the thresholds for drug and light doses required to get a PDT effect in normal rat colon and to Figure 3 where most of the PPIX over a 1 cm zone at the treatment site has been photodegraded by a light dose of 50 J. Similar results have been obtained with AlSPc (Barr et al., 1990; Bedwell et al., 1991) although the threshold dose for AlSPc is much lower at about 0.5 mg kg-'.
It is difficult to extrapolate directly from rats to humans to correlate absolute tissue levels of PPIX with the administered dose of ALA without chemical extraction data. However we do have fluorescence photometric data recorded using the same calibration conditions from frozen sections (Loh et al.. 1993a (Loh et al.. , 1993b Regula et al., 1995) of rat colon and human colonic biopsies which indicate that the maximum dose we used clinically (60 mg kg' by mouth) is very close to the threshold level found in the present experiments. Therefore it is perhaps not surprising that the clinical effects were so superficial. Nevertheless, some PDT necrosis was seen in our clinical study, which suggests that it may not be necessary to raise the tissue levels of PPIX very much in order to get a much larger effect. This problem may be solved when an intravenous preparation of ALA is available for clinical use, but another possibility is to give an iron chelating agent in order to inhibit the conversion of PPIX to haem and thus temporarily raise the tissue levels of PPIX. We have already shown that the mucosal level of PPIX in the rat bladder can be doubled by simultaneous administration of the iron chelating agent 1,2-diethyl-3-hydroxypyridine-4-one (CP94) (Chang et al., 1995) , although this has not yet been tested clinically.
At the upper end of the range of ALA doses used here, doubling the dose of ALA from 200 to 400 mg kg' only produced a marginal increase in the area of the mucosal lesion. The most likely explanation for this is that the enzyme systems in the synthetic chain from ALA to PPIX became saturated thus limiting PPIX synthesis (Pottier et al., 1986) , so there is no point in giving an ALA dose more than 100-200mgkg-l. Thus there seems to be a fairly narrow band of effective doses of ALA. in the range 50-200mg kgGeneral comments can also be made on the range of useful light doses. For ALA doses greater than 25 mg kg-', the area of necrosis increases with higher light doses, but little is gained by increasing the light dose above 100 J (Figure 2 ). Some effect is produced with 25 J. but with the lower doses of ALA, at least 50 J is required to produce a lesion of worthwhile size. Thus the useful range of light doses in this experimental model is quite small, between 50 and 100 J. Naturally, the light doses required in any particular situation will depend on the geometry and on the organ being treated. but these results do suggest that there is nothing to be gained by large increases in the doses of light. It has been speculated that the use of polychromatic light over the 600-700 nm range might enhance PDT with ALA through the conco- Table V (Table I) ; all of the observed increases above the control value were well in excess of variations from experimental error. The data in Table II (when five fractions were used) suggest that the effect increases slightly as the duration of the break between fractions increases, although in Table I (just two fractions) this trend is not seen. Table III shows that the use of two fractions divided by a 50s interval appears to be optimum with five fractions being slightly less effective but still a factor of two above the control value. It appears therefore that as long as there is at least one break in treatment, the number of breaks is not crucial.
Our experiments using 25 J and fractionated light produced lesions similar in size to those seen with continuous light doses of more than 100J. Clinically, this could mean that the light dose can be reduced by a factor of four, which would be a considerable improvement. In our first experiments with just two fractions, the length of the break between fractions had little effect on the result (Table I) although with five fractions the lesion size appeared to increase as the interval was increased from 10 to 150 s. Experiments with larger numbers of animals would be required to establish how important this effect is overall. It could be relevant if new PPIX synthesis during the interval is important, but this is unlikely as the interval durations studied here are short compared with the time required for PPIX synthesis (van der Veen et al., 1994) .
The most likely reason for the effect of fractionation is related to tissue oxygenation and vascular shut-down. (Star et al., 1986) . Oxygen is an essential component of the PDT effect (Bown et al., 1986; Star et al., 1986) (Wieman and Fingar, 1992) where it is noted that experimental studies of ischaemic injury have shown that temporary interruption of the regional blood flow leads to the release of oxygen radicals upon reperfusion (Klausener, 1989) . Such an effect may well be involved in the enhanced response with fractionated PDT treatment if reperfusion is a significant effect during the intervals between irradiation.
Previous studies have compared continuous wave and pulsed laser sources for PDT and showed that there is no difference in the effect with high repetition rates (I-10kHz with pulse widths of 10-40 ns) although no PDT effect was seen with a flashlamp pumped dye laser delivering higher intensity pulses with a repetition rate of < 10 Hz and pulses of 2-400 ps duration (Cowled et al., 1984; Barr et al., 1989; Ferrario et al., 1991; Panjehpour et al., 1993) . This absence of a PDT response at lower repetition rates was attributed to saturation pumping of the sensitiser resulting in depopulation of the ground absorbing state. This transient bleaching effect however can only occur using high power pulsed excitation as opposed to fractionated irradiation. Recently, there have been two papers looking at the effect of dividing the light into two fractions. Van der Veen et al. (1994) showed that two light fractions 90 min apart enhanced the PDT effect in a rat tumour model, but as the total delivered energy was doubled when the light was fractionated, it is not clear whether they were observing the same effect as us. Pe et al. (1994) studied the destruction of a transplanted tumour in mice after PDT with haematoporphyrin oligomer photosensitisation comparing a single treatment for 20 min with two 30 min treatments separated by 1 h, the total light dose being the same for the two regimens. They found that the fractionated regimen considerably enhanced the PDT effect. These results are certainly consistent with ours. Foster et al. (1991) have also demonstrated, using modulated irradiation with a period of 30s, that a markedly improved tumour response with Photofrin can be achieved; although in our studies modulation with a 50 s period also proved effective, the degree of enhancement was greatest using a fractionated protocol.
In conclusion, although the maximum tissue levels of PPIX achieved in patients using oral ALA are probably only at or just above the threshold level for producing any effect, our experimental results indicate once the threshold level is exceeded, the efficacy is much greater, which implies that a useful clinical response could yet be achieved. In order to increase the PPIX levels ALA could be given intravenously and/or by coadministering an iron-chelating agent. Alternatively, by fractionating the light dose, even with low PPIX levels present, a significant improvement in the therapeutic response may be achievable.
